loncastuximab tesirine + polatuzumab vedotin

**Loncastuximab tesirine + polatuzumab vedotin** is an investigational combination therapy for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and Burkitt lymphoma[1][2][3][7]. - **Loncastuximab tesirine** (Zynlonta, ADCT-402) is a CD19-directed antibody-drug conjugate composed of a humanized monoclonal antibody linked via a cathepsin-cleavable linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin[1][2][5][6]. After binding to CD19, it is internalized and delivers the PBD payload, forming covalent DNA crosslinks and inducing cell death[6]. - **Polatuzumab vedotin** (Polivy) is a CD79b-directed antibody-drug conjugate comprising a humanized anti-CD79b monoclonal antibody conjugated to monomethyl auristatin E (MMAE), an anti-mitotic agent that disrupts microtubules and induces cancer cell apoptosis[2][8]. The combination leverages the distinct B-cell targets (CD19, CD79b), aiming for increased anti-tumor activity and overcoming resistance mechanisms. Both drugs are approved separately for DLBCL; their combination is currently under Phase 1b clinical investigation for B-cell NHL[1][2][3][7].

Other names

loncastuximab tesirineloncastuximab tesirine-lpylADCT-402ADCT402ADCT 402polatuzumab vedotinPolivy